Details of the Drug
General Information of Drug (ID: DM2AQ5N)
Drug Name |
Spironolactone
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Abbolactone; Acelat; Aldace; Aldactazide; Aldactide; Aldactone; Alderon; Aldopur; Almatol; Altex; Aquareduct; Deverol; Diatensec; Dira; Duraspiron; Espironolactona; Euteberol; Flumach; Frumikal; Jenaspiron; Lacalmin; Lacdene; Laractone; Melarcon; Nefurofan; NovoSpiroton; Osyrol; Practon; SNL; Sagisal; Sincomen; Spiractin; Spiresis; Spiretic; Spiridon; Spirobeta; Spiroctan; Spiroctanie; Spiroderm; Spirogamma; Spirolactone; Spirolakton; Spirolang; Spirolone; Spirone; Spironocompren; Spironolactonum; Spironolattone; Spironone; Spirospare; Sprioderm; Suracton; Uractone; Urusonin; Veroshpiron; Verospiron; Verospirone; Xenalon; Aldactone A; Alphapharm Brand of Spironolactone; Alpharma Brand of Spironolactone; Alter Brand of Spironolactone; Ashbourne Brand of Spironolactone; Azupharma Brand of Spironolactone; Betapharm Brand of Spironolactone; Cardel Brand of Spironolactone; Ct Arzneimittel Brand of Spironolactone; Dexo Brand of Spironolactone; Espironolactona Alter; Espironolactona Mundogen; Generosan Brand of Spironolactone; Hormosan Brand of Spironolactone; Jenapharm Brand of Spironolactone; Merck dura Brand of Spironolactone; Mundogen Brand of Spironolactone; Novo Spiroton; Novopharm Brand of Spironolactone; Pfizer Brand of Spironolactone; Pharmafrid Brand of Spironolactone; Roche Brand of Spironolactone; Searle Brand of Spironolactone; Spiro von ct; Spirono Isis; Spironolactone A; Spironolattone [DCIT]; Verospirone Opianin; Worwag Brand of Spironolactone; LT00772287; SC 9420; SC9420; Aldactazide (TN); Aldactone (TN); Berlactone (TN); Ct-Arzneimittel Brand of Spironolactone; Espironolactona [INN-Spanish]; Mayoly-Spindler Brand of Spironolactone; Novo-Spiroton; SC-9420; Spiractin (TN); Spiro-Tablinen; Spirono-Isis; Spironolactonum [INN-Latin]; Spirotone (TN); Supra-puren; Verospiron (TN); Von ct, spiro; Novo-Spiroton (TN); Spironolactone [BAN:INN:JAN]; Spironolactone [INN:BAN:JAN]; Spiro L.U.T.; Spironolactone (JP15/USP/INN); Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]; Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan); 4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate; 7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone; 7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Therapeutic Class |
Diuretics
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 416.6 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2.9 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Congestive heart failure | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | BD10 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Same Disease as Spironolactone
Coadministration of a Drug Treating the Disease Different from Spironolactone (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2875). | ||||
---|---|---|---|---|---|
2 | Emerging drugs for complications of end-stage liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):159-74. | ||||
3 | BDDCS applied to over 900 drugs | ||||
4 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
6 | Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42. | ||||
7 | Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. | ||||
8 | Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. | ||||
9 | Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. | ||||
10 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
11 | ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43. | ||||
12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). | ||||
13 | Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. | ||||
14 | Marcy TR, Ripley TL "Aldosterone antagonists in the treatment of heart failure." Am J Health Syst Pharm 63 (2006): 49-58. [PMID: 16373465] | ||||
15 | Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783] | ||||
16 | Product Information. Aldactone (spironolactone). Searle, Skokie, IL. | ||||
17 | Multum Information Services, Inc. Expert Review Panel. | ||||
18 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
19 | Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424] | ||||
20 | Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028] | ||||
21 | Adachi Y, Suzuki H, Sugiyama Y "Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in Situ and in Vivo." Pharm Res 20 (2003): 1163-9. [PMID: 12948013] | ||||
22 | Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
23 | Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.". | ||||
24 | Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049] | ||||
25 | Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO. | ||||
26 | Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA. | ||||
27 | Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002] | ||||
28 | Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA. | ||||
29 | Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330] | ||||
30 | Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA. | ||||
31 | Cerner Multum, Inc. "Australian Product Information.". | ||||
32 | Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA. | ||||
33 | Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC. | ||||
34 | Product Information. Midamor (amiloride). Merck & Co, Inc, West Point, PA. | ||||
35 | Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
36 | Jarman PR, Mather HM "Diabetes may be independent risk factor for hyperkalaemia." BMJ 327 (2003): 812. [PMID: 14525902] | ||||
37 | McNay JL, Oran E "Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870)." Metabolism 19 (1970): 58-70. [PMID: 5410663] | ||||
38 | Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD. | ||||
39 | Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC. | ||||
40 | Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA. | ||||
41 | Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA. | ||||
42 | Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA. | ||||
43 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
44 | Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA. | ||||
45 | Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA. | ||||
46 | Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990] | ||||
47 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
48 | Perazella MA "Drug-induced hyperkalemia: old culprits and new offenders." Am J Med 109 (2000): 307-14. [PMID: 10996582] | ||||
49 | Canaday DH, Johnson JR "Hyperkalemia in elderly patients receiving standard doses of trimethoprim-sulfamethoxazole." Ann Intern Med 120 (1994): 438. [PMID: 8304666] | ||||
50 | Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ. | ||||